Parafluorofentanyl
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide | |
| Clinical data | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
90736-23-5  |
| ATC code | none |
| PubChem | CID 62300 |
| ChemSpider |
56096 |
| UNII |
I45R05QM0Z |
| ChEBI |
CHEBI:61074 |
| Chemical data | |
| Formula | C22H27FN2O |
| Molar mass | 354.461 g/mol |
| |
| |
| (verify) | |
Parafluorofentanyl (4-Fluorofentanyl) is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s.[1]
4-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.[2] 4-Fluorofentanyl is made with the same synthetic route as fentanyl, but by substituting para-fluoroaniline for aniline in the synthesis.[3]
Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[4]
See also
- 3-Methylbutyrfentanyl
- 3-Methylfentanyl
- 4-Fluorobutyrfentanyl
- α-Methylfentanyl
- Acetylfentanyl
- Butyrfentanyl
- Furanylfentanyl
- List of Fentanyl analogues
References
- ↑ US patent 3164600
- ↑ Henderson, G. L. (1988). "Designer Drugs: Past History and Future Prospects". Journal of Forensic Sciences 33 (2): 569–575. PMID 3286815.
- ↑ Ulens, C.; Van Boven, M.; Daenens, P.; Tytgat, J. (2000). "Interaction of p-Fluorofentanyl on Cloned Human Opioid Receptors and Exploration of the Role of Trp-318 and His-319 in μ-Opioid Receptor Selectivity" (pdf). The Journal of Pharmacology and Experimental Therapeutics 294 (3): 1024–1033. PMID 10945855.
- ↑ Jane Mounteney, Isabelle Giraudon, Gleb Denissov, Paul Griffiths (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.". The international journal of drug policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.